top of page

Revolutionizing Treatment for Immune-Mediated Diseases with Sotyktu (deucravacitinib)


The world of medicine is continuously evolving, with new breakthroughs and discoveries happening every day. One such breakthrough is Sotyktu (deucravacitinib), an innovative drug designed to target and inhibit the signaling of key cytokines involved in the pathogenesis of various immune-mediated diseases.

Understanding Sotyktu (deucravacitinib)

Sotyktu, also known as deucravacitinib, belongs to a unique class of small molecules. It is an oral, selective, allosteric inhibitor of Tyrosine Kinase 2 (TYK2). This pioneering drug has been scientifically designed to selectively target TYK2, thereby inhibiting the signaling of interleukin (IL)-23, IL-12, and Type 1 interferons (IFN). These are key cytokines involved in multiple immune-mediated diseases.

The drug achieves a high degree of selectivity by binding to the regulatory domain of TYK2, resulting in allosteric inhibition of TYK2 and its downstream functions. At therapeutic doses, Sotyktu does not inhibit JAK1, JAK2, or JAK3, making it an ideal choice for patients with immune-mediated diseases.

The Driving Force: Bristol Myers Squibb

"Transforming patients' lives through science" - Bristol Myers Squibb

Bristol Myers Squibb, the company behind Sotyktu, is driven by a vision to transform patients' lives through science. For many patients, chronic symptoms and disease progression take a toll on their physical, emotional, and social well-being. Bristol Myers Squibb, with over 20 years of experience in immunology, aims to alleviate this burden through pathbreaking science.

Indications for Sotyktu

Sotyktu has been indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. However, it is not recommended for use in combination with other potent immunosuppressants.

Safety Information

As with any medication, it's important to be aware of potential side effects and precautions. Sotyktu is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or any other components of the drug.


Reported hypersensitivity reactions include angioedema. If a clinically significant hypersensitivity reaction occurs, appropriate therapy should be instigated, and Sotyktu should be discontinued.


Sotyktu could potentially increase the risk of infections, with serious infections reported in some patients with psoriasis. These included pneumonia and COVID-19. It is recommended that the drug should not be used in patients with an active or serious infection.

Viral Reactivation

Viral reactivation, such as herpes virus reactivation (e.g., herpes zoster, herpes simplex), has been reported in clinical trials. In case of signs of reactivation, a hepatitis specialist should be consulted.

Tuberculosis (TB)

Patients should be evaluated for latent and active TB infection before starting treatment with Sotyktu. The drug should not be administered to patients with active TB.


There have been instances of malignancies, including lymphomas, reported in clinical trials with Sotyktu. The benefits and risks should be considered before initiating or continuing therapy.


In conclusion, Sotyktu (deucravacitinib) represents a new class of small molecules that holds great promise for the treatment of immune-mediated diseases. It's a testament to the relentless pursuit of Bristol Myers Squibb to transform patients' lives through innovative treatments.


Disclaimer: This article is intended for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.


Recent Posts

See All


bottom of page